1380445-03-3

Basic information

• Product Name: 4-(((1S,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid
• Synonyms: 4-(((1S,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid
• CAS NO: 1380445-03-3
• Molecular Weight: 382.459
• Mol File: 1380445-03-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(((1S,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(((1S,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid(1380445-03-3)
• EPA Substance Registry System: 4-(((1S,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid(1380445-03-3)

Safety Data

• Hazardous Substances Data: 1380445-03-3(Hazardous Substances Data)

Upstream product

• 31928-64-0 1-trimethylsilyloxy-3H-indene 
• 192194-67-5 methyl 4-((2,3-dihydro-2-(1H-inden-2-yl)-1-oxo-1H-inden-2-yl)methyl)benzoate 
• 192194-60-8 2,3-dihydro-2-(2,3-dihydro-2-methoxy-1H-inden-2-yl)inden-1-one 

Downstream Products

• 1380445-04-4 (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentanol 4-(((1S,2S)-1-hydroxy-2,3-dihydro-1H,1'H-[2,2-biinden]-2-yl)methyl)benzoic acid 
• 1421008-69-6 (S)-1-phenylethylammonium 4-(((1S,2S)-1-hydroxy-2,3-dihydro-1H,1'H-[2,2'-biinden]-2-yl)methyl)benzoate 
• 1421332-97-9 methyl 4-(((1S,2S)-1-hydroxy-2,3-dihydro-1H,1'H-[2,2'-biinden]-2-yl)methyl)benzoate 
• 1421333-11-0 4-{[(1'S,2'S)-1'-(L-isoleucyloxy)-1',3'-dihydro-1H,2'H-2,2'-biinden-2'-yl]methyl}benzoic acid 
• 1421333-10-9 4-{[(1'S,2'S)-1'-(L-valyloxy)-1',3'-dihydro-1H,2'H-2,2'-biinden-2'-yl]methyl}benzoic acid 
• 1421333-08-5 4-{[(1'S,2'S)-1'-(L-leucyloxy)-1',3'-dihydro-1H,2'H-2,2'-biinden-2'-yl]methyl}benzoic acid 
• 1421333-03-0 4-{[(1'S,2'S)-1'-hydroxy-1',3'-dihydro-1H,2'H-2,2'-biinden-2'-yl]methyl}-N,N-dimethylbenzamide 
• 1421333-02-9 4-{[(1'S,2'S)-1'-hydroxy-1',3'-dihydro-1H,2'H-2,2'-biinden-2'-yl]methyl}-N-methylbenzamide 
• 1421333-01-8 4-{[(1'S,2'S)-1'-hydroxy-1',3'-dihydro-1H,2'H-2,2'-biinden-2'-yl]methyl}-N-(2-hydroxyethyl)benzamide 
• 1421332-99-1 propyl 4-(((1S,2S)-1-hydroxy-2,3-dihydro-1H,1'H-[2,2'-biinden]-2-yl)methyl)benzoate 
• 1421332-98-0 ethyl 4-(((1S,2S)-1-hydroxy-2,3-dihydro-1H,1'H-[2,2'-biinden]-2-yl)methyl)benzoate 
• 1421333-23-4 (1S,2S)-2-(4-carbamoylbenzyl)-2,3-dihydro-1H,1'H-2,2'-biinden-1-yl L-leucinate 
• 1421333-22-3 propyl 4-(((1S,2S)-1-(((S)-2-amino-4-methylpentanoyl)oxy)-2,3-dihydro-1H,1'H-[2,2'-biinden]-2-yl)methyl)benzoate 
• 1421333-21-2 ethyl 4-(((1S,2S)-1-(((S)-2-amino-4-methylpentanoyl)oxy)-2,3-dihydro-1H,1'H-[2,2'-biinden]-2-yl)methyl)benzoate 

Relevant articles and documents

INDANE DIMERS FOR USE IN THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASE

Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the formula: wherein R is selected from one or more of the same or different of hydrogen, hydroxyl, optionally substituted alkyl, optionally substituted aryl, alkoxy, aryloxy, thiol, and optionally substituted amino, and wherein R1 is selected from one or more of the same or different of hydrogen, acetyl, optionally substituted alkyl, optionally substituted aryl, and an amino acid selected from leucine, valine, isoleucine, and glycine.

6-(Methylamino)hexane-1,2,3,4,5-pentanol 4-(((1 S,2 S)-1-hydroxy-2,3- dihydro-1 H,1′ H -[2,2-biinden]-2-yl)methyl)benzoate (PH46A): A novel small molecule with efficacy in murine models of colitis

The indane skeleton is found naturally and in several therapeutic molecules in medicinal chemistry. During our work on the anti-inflammatory activity of naturally occurring and synthetic indanes, we have synthesized a novel indane scaffold that has been optimized for both anti-inflammatory activity and bioavailability. We have evaluated our lead molecule, PH46A, in in vivo models of inflammatory bowel disease (IBD), an area of considerable unmet clinical need; current therapies are often unable to control the course of the disease. The compound significantly reduced histological damage and serum amyloid A (SAA) levels in IL-10-/- colitis mice, was efficacious in the 5% dextran sulfate sodium (DSS) colitis model, and compared favorably with prednisolone in this model and supports its potential use to treat acute exacerbations of the disease. Further, the graded response to the compound may also lend itself to be used at a lower dose to maintain periods of remission.